Under the Influence: The Interplay among Industry, Publishing, and Drug Regulation

Accountability in Research

Volumn 23, Issue 5, 2016, Pages 257-279

  Cosgrove, Lisa ^a   Vannoy, Steven ^a   Mintzes, Barbara ^b   Shaughnessy, Allen F ^c  

^a UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; clinical trials; conflict of interest; ghostwriting; medical journals; regulatory process

Indexed keywords

ANTIDEPRESSANT AGENT; PIPERAZINE DERIVATIVE; SULFIDE; VORTIOXETINE;

CONFLICT OF INTEREST; DRUG INDUSTRY; DRUG LEGISLATION; ETHICS; EUROPE; FOOD AND DRUG ADMINISTRATION; HUMAN; ORGANIZATION AND MANAGEMENT; PUBLISHING; STATISTICAL BIAS; UNITED STATES;

ANTIDEPRESSIVE AGENTS; BIAS (EPIDEMIOLOGY); CONFLICT OF INTEREST; DRUG INDUSTRY; EUROPE; HUMANS; LEGISLATION, DRUG; PIPERAZINES; PUBLISHING; SULFIDES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84964931609     PISSN: 08989621     EISSN: 15455815     Source Type: Journal    
DOI: 10.1080/08989621.2016.1153971     Document Type: Article

References (59)

1. E.Alvarez,, V.Perez, M.Dragheim, H.Loft, and F.Artigas. 2012. A double-blind, randomized, placebo-controlled, active reference study of lu aa21004 in patients with major depressive disorder. The International Journal of Neuropsychopharmacology 15 (5):589–600. doi:10.1017/S1461145711001027.
2. M.Angell, 2004. The truth about the drug companies: How they deceive us and what to do about it. New York, NY: Random House.
3. J.Avorn, 2005. Powerful medicines: The benefits, risks, and costs of prescription drugs, Revised Edition. New York, NY: Vintage Books.
4. A.Baciu,, K.Stratton, and S.P.Burke, editors. 2006. The future of drug safety: Protecting the health of the public. Washington, DC: Institute of Medicine, National Academies Press.
5. D.S.Baldwin,, H.Loft, and M.Dragheim. 2012. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of lu aa21004 in acute treatment of major depressive disorder (mdd). European Neuropsychopharmacology 22 (7):482–91. doi:10.1016/j.euroneuro.2011.11.008.
6. L.A.Bero,, and D.Rennie. 1996. Influences on the quality of published drug studies. International Journal of Technology Assessment in Health Care 12 (2):209–37. doi:10.1017/S0266462300009582.
7. K.Borgerson, 2014. Redundant, secretive, and isolated: When are clinical trials scientifically valid? Kennedy Institute of Ethics Journal 24 (4):385–411. doi:10.1353/ken.2014.0029.
8. J.P.Boulenger,, H.Loft, and I.Florea. 2012. A randomized clinical study of lu aa21004 in the prevention of relapse in patients with major depressive disorder. Journal of Psychopharmacology 26 (11):1408–16. doi:10.1177/0269881112441866.
9. J.P.Boulenger,, H.Loft, and C.K.Olsen. 2014. Efficacy and safety of vortioxetine (lu aa21004), 15 and 20 mg/day: A randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. International Clinical Psychopharmacology 29 (3):138–49. doi:10.1097/YIC.0000000000000018.
10. Center for Drug Evaluation and Research. (2012). Medical reviews (s). Application Number: 204447Orig1s000 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204447orig1s000medr.pdf (accessed March 1, 2016).
11. L.Cosgrove,, A.F.Shaughnessy, E.E.Wheeler, S.Krimsky, S.M.Peters, D.J.Freeman-Coppadge, and J.R.Lexchin. 2014. From caveat emptor to caveat venditor: Time to stop the influence of money on practice guideline development. Journal of Evaluation in Clinical Practice 20 (6):809–12. doi:10.1111/jep.12244.
12. L.Cosgrove,, and S.Krimsky. 2012. A comparison of DSM- IV and DSM-5 panel members’ financial associations with industry: A pernicious problem persists. PLoS Med 9:e1001190. doi:10.1371/journal.pmed.1001190.
13. M.Doucet,, and S.Sismondo. 2008. Evaluating solutions to sponsorship bias. Journal of Medical Ethics 34 (8):627–30. doi:10.1136/jme.2007.022467.
14. C.Elliott, 2004. Pharma goes to the laundry: Public relations and the business of medical education. The Hastings Center Report 34 (5):18–23. doi:10.2307/3527586.
15. K.C.Elliott, 2008. Scientific judgment and the limits of conflict-of-interest policies. Accountability in Research 15 (1):1–29. doi:10.1080/08989620701783725.
16. European Medicines Agency. 2014. Committee for Medicinal Products for Human Use. A Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Vortioxetine in Patients with Major Depressive Disorder. Described in: Brintellix (vortioxetine), Applicant: H. Lundbeck A/S Assessment Report for an initial marketing authorisation application. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002717/WC500159447.pdf (accessed March 1, 2016).
17. A.J.Fugh-Berman, 2010. The haunting of medical journals: How ghostwriting sold “hrt”. PLoS Med 7 (9):e1000335. doi:10.1371/journal.pmed.1000335.
18. E.J.Garland, 2004. Facing the evidence: Antidepressant treatment in children and adolescents. Cmaj 170 (4):489–91.
19. B.Goldacre, 2013. Bad pharma: How drug companies mislead doctors and harm patients. First American edition. New York, NY: Faber and Faber, Inc., an affiliate of Farrar, Straus and Giroux.
20. Goodrx.com (2015) Brintellix. http://www.goodrx.com/brintellix (accessed 16 February 2015).
21. D.Healy,, and D.Cattell. 2003. Interface between authorship, industry and science in the domain of therapeutics. The British Journal of Psychiatry: The Journal of Mental Science 182:18322–27.
22. A.Hedgecoe, 2014. A deviation from standard design? Clinical trials, research ethics committees, and the regulatory co-construction of organizational deviance. Social Studies of Science 44 (1):59–81. doi:10.1177/0306312713506141.
23. N.Henigsberg,, A.R.Mahableshwarkar, P.Jacobsen, Y.Chen, and M.E.Thase. 2012. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of lu aa21004 in adults with major depressive disorder. The Journal of Clinical Psychiatry 73 (7):953–59. doi:10.4088/JCP.11m07470.
24. S.Heres,, J.Davis, K.Maino, E.Jetzinger, W.Kissling, and S.Leucht. 2006. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. American Journal of Psychiatry 163 (2):185–94. doi:10.1176/appi.ajp.163.2.185.
25. J.P.T.Higgins,, and S.Green; Cochrane Collaboration. 2008. Cochrane handbook for systematic reviews of interventions Cochrane book series. Chichester, England; Hoboken, NJ: Wiley-Blackwell.
26. J.P.T.Higgins,, and S.Green (eds.). 2011. Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, www.cochrane-handbook.org.
27. P.L.Jacobsen,, A.R.Mahableshwarkar, M.Serenko, S.Chan, and M.H.Trivedi. 2015. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. The Journal of Clinical Psychiatry 76 (5):575–82. doi:10.4088/JCP.14m09335.
28. R.Jain,, A.R.Mahableshwarkar, P.L.Jacobsen, Y.Chen, and M.E.Thase. 2013. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. The International Journal of Neuropsychopharmacology 16 (2):313–21. doi:10.1017/S1461145712000727.
29. J.N.Jureidini,, and L.B.McHenry. 2011. Conflicted medical journals and the failure of trust. Accountability in Research 18 (1):45–54. doi:10.1080/08989621.2011.542683.
30. C.Katona,, T.Hansen, and C.K.Olsen. 2012. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of lu aa21004 in elderly patients with major depressive disorder. International Clinical Psychopharmacology 27 (4):215–23. doi:10.1097/YIC.0b013e3283542457.
31. A.S.Kesselheim,, B.Wang, D.M.Studdert, and J.Avorn. 2012. Conflict of interest reporting by authors involved in promotion of off-label drug use: An analysis of journal disclosures. PLoS Med 9 (8):e1001280. doi:10.1371/journal.pmed.1001280.
32. F.Koenig,, J.Slattery, T.Groves, T.Lang, Y.Benjamini, S.Day, P.Bauer, and M.Posch. 2015. Sharing clinical trial data on patient level: Opportunities and challenges. Biometrical Journal. Biometrische Zeitschrift 57 (1):8–26. doi:10.1002/bimj.v57.1.
33. S.Kousar,, Z.A.Wafai, M.A.Wani, T.R.Jan, and K.I.Andrabi. 2015. Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: Validatory pharmacogenomic approach to pharmacovigilance. International Journal of Clinical Pharmacology and Therapeutics 53 (7):504–16. doi:10.5414/CP202112.
34. S.Krimsky, 2003. Science in the private interest: Has the lure of profits corrupted biomedical research? Lanham, MD: Rowman & Littlefield Publishers.
35. S.Krimsky, 2013. Do financial conflicts of interest bias research?: An inquiry into the “funding effect” hypothesis. Science, Technology & Human Values 38 (4):566–87. doi:10.1177/0162243912456271.
36. J.R.Lacasse,, and J.Leo. 2010. Ghostwriting at elite academic medical centers in the united states. PLoS Med 7 (2):e1000230. doi:10.1371/journal.pmed.1000230.
37. J.Le Noury,, J.M.Nardo, D.Healy, J.Jureidini, M.Raven, C.Tufanaru, and E.Abi-Jaoude. 2015. Restoring study 329: Efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. Bmj 351:h4320.
38. L.Lessig, 2013. Foreword: “Institutional corruption” defined. The Journal of Law, Medicine & Ethics: A Journal of the American Society of Law, Medicine & Ethics 41 (3):553–55. doi:10.1111/jlme.12063.
39. J.Lexchin,, and D.W.Light. 2006. Commercial influence and the content of medical journals. Bmj 332 (7555):1444–47. doi:10.1136/bmj.332.7555.1444.
40. Y.K.Loke,, and K.Mattishent. 2015. If nothing happens, is everything all right? Distinguishing genuine reassurance from a false sense of security. Cmaj 187 (1):15–16. doi:10.1503/cmaj.141344.
41. A.Lundh,, S.Sismondo, J.Lexchin, O.A.Busuioc, and L.Bero. 2012. Industry sponsorship and research outcome. Cochrane Database Syst Rev 12:MR000033.
42. A.R.Mahableshwarkar,, P.L.Jacobsen, and Y.Chen. 2013. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (lu aa21004) versus placebo for 8 weeks in adults with major depressive disorder. Current Medical Research and Opinion 29 (3):217–26. doi:10.1185/03007995.2012.761600.
43. A.R.Mahableshwarkar,, P.L.Jacobsen, Y.Chen, M.Serenko, and M.H.Trivedi. 2015. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with mdd. Psychopharmacology (Berl) 232 (12):2061–70. doi:10.1007/s00213-014-3839-0.
44. A.R.Mahableshwarkar,, P.L.Jacobsen, M.Serenko, Y.Chen, and M.H.Trivedi. 2015b. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. The Journal of Clinical Psychiatry 76 (5):1–478. doi:10.4088/JCP.14m09337.
45. L.B.McHenry,, and J.N.Jureidini. 2008. Industry-sponsored ghostwriting in clinical trial reporting: A case study. Accountability in Research 15 (3):152–67. doi:10.1080/08989620802194384.
46. R.S.McIntyre,, S.Lophaven, and C.K.Olsen. 2014. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. The International Journal of Neuropsychopharmacology 17 (10):1557–67. doi:10.1017/S1461145714000546.
47. A.S.Meeker,, M.C.Herink, D.G.Haxby, and D.M.Hartung. 2015. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: A systematic review and meta-analysis. Systematic Reviews 4:21. doi:10.1186/s13643-015-0001-y.
48. C.U.Pae,, S.M.Wang, C.Han, S.J.Lee, A.A.Patkar, P.S.Masand, and A.Serretti. 2015. Vortioxetine: A meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. Journal of Psychiatry & Neuroscience: JPN 40 (3):174–86. doi:10.1503/jpn.140120.
49. T.V.Pereira,, R.I.Horwitz, and J.P.Ioannidis. 2012. Empirical evaluation of very large treatment effects of medical interventions. Jama 308 (16):1676–84. doi:10.1001/jama.2012.13444.
50. D.B.Resnik,, and K.C.Elliott. 2013. Taking financial relationships into account when assessing research. Accountability in Research 20 (3):184–205. doi:10.1080/08989621.2013.788383.
51. A.E.Shamoo, 2001. Adverse events reporting–the tip of an iceberg. Accountability In Research 8 (3):197–218. doi:10.1080/08989620108573974.
52. A.F.Shaughnessy,, and D.C.Slawson. 2003. What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes. BMJ: British Medical Journal (International Edition) 327 (7409):266. doi:10.1136/bmj.327.7409.266.
53. A.Shnier,, J.Lexchin, B.Mintzes, A.Jutel, and K.Holloway. 2013. Too few, too weak: Conflict of interest policies at Canadian medical schools. PLoS One 8 (7):e68633. doi:10.1371/journal.pone.0068633.
54. S.Sismondo, 2009. Ghosts in the machine: Publication planning in the medical sciences. Social Studies of Science 39 (2):171–98. doi:10.1177/0306312708101047.
55. R.Smith, 2005. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Medicine 2 (5):e138. doi:10.1371/journal.pmed.0020138.
56. P.M.Tereskerz,, A.B.Hamric, T.M.Guterbock, and J.D.Moreno. 2009. Prevalence of industry support and its relationship to research integrity. Accountability in Research 16 (2):78–105. doi:10.1080/08989620902854945.
57. E.H.Turner,, A.M.Matthews, E.Linardatos, R.A.Tell, and R.Rosenthal. 2008. Selective publication of antidepressant trials and its influence on apparent efficacy. The New England Journal of Medicine 358 (3):252–60. doi:10.1056/NEJMsa065779.
58. G.Wang, M.Gislum, G.Fillipov, and S.Montgomery. 2015. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: A randomized, double-blind study. Current Medical Research & Opinion 31 (4):785–794.
59. S.R.Wisniewski,, A.J.Rush, A.A.Nierenberg, B.N.Gaynes, D.Warden, J.F.Luther, P.J.McGrath, P.W.Lavori, M.E.Thase, M.Fava, and M.H.Trivedi. 2009. Can phase iii trial results of antidepressant medications be generalized to clinical practice? A star*d report. American Journal of Psychiatry 166 (5):599–607. doi:10.1176/appi.ajp.2008.08071027.